^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vevoctadekin (ST-067)

    i
    Associations
    News

    Trials

    Company:
    Simcha Therap
    Drug class:
    IL-18 stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (KEYNOTE-E64) (NCT04787042)
    Phase 1/2
    Simcha IL-18, Inc.
    Recruiting
    Last update posted :
    11/15/2024
    Initiation :
    08/06/2021
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    ALK • TMB • MSI
    |
    TMB-H • MSI-H/dMMR • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)